Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | CARA |
---|---|---|
09:32 ET | 11298 | 0.7906 |
09:34 ET | 598 | 0.795 |
09:39 ET | 600 | 0.7946 |
09:41 ET | 3775 | 0.77485 |
09:43 ET | 100 | 0.7755 |
09:45 ET | 5660 | 0.7925 |
09:48 ET | 2100 | 0.7838 |
09:52 ET | 100 | 0.7925 |
09:54 ET | 300 | 0.7924 |
09:56 ET | 100 | 0.7751 |
09:57 ET | 100 | 0.7755 |
09:59 ET | 100 | 0.7755 |
10:03 ET | 722 | 0.7756 |
10:06 ET | 1080 | 0.7571 |
10:08 ET | 108 | 0.76845 |
10:12 ET | 103 | 0.76845 |
10:15 ET | 100 | 0.768449 |
10:17 ET | 100 | 0.76845 |
10:19 ET | 12000 | 0.77479 |
10:24 ET | 100 | 0.7571 |
10:28 ET | 500 | 0.773512 |
10:30 ET | 425 | 0.7571 |
10:39 ET | 100 | 0.76 |
10:42 ET | 100 | 0.7775 |
10:46 ET | 1941 | 0.7775 |
10:53 ET | 600 | 0.7627 |
11:04 ET | 100 | 0.7775 |
11:08 ET | 100 | 0.7701 |
11:09 ET | 100 | 0.7627 |
11:15 ET | 100 | 0.7775 |
11:27 ET | 3026 | 0.7775 |
11:29 ET | 700 | 0.7716 |
11:31 ET | 7800 | 0.7825 |
11:33 ET | 600 | 0.784 |
11:42 ET | 658 | 0.7875 |
11:44 ET | 1350 | 0.7859 |
11:45 ET | 100 | 0.7945 |
11:47 ET | 1950 | 0.7859 |
11:56 ET | 300 | 0.7806 |
11:58 ET | 161 | 0.7828 |
12:02 ET | 100 | 0.7805 |
12:12 ET | 291 | 0.7769 |
12:14 ET | 800 | 0.7716 |
12:20 ET | 200 | 0.7716 |
12:27 ET | 100 | 0.7716 |
12:30 ET | 100 | 0.7716 |
12:32 ET | 1400 | 0.78 |
12:34 ET | 175 | 0.775 |
12:43 ET | 200 | 0.7716 |
12:50 ET | 700 | 0.7725 |
12:54 ET | 100 | 0.7733 |
12:56 ET | 3813 | 0.775 |
12:57 ET | 1000 | 0.775 |
12:59 ET | 850 | 0.7774 |
01:01 ET | 2225 | 0.78 |
01:03 ET | 2405 | 0.7801 |
01:06 ET | 285 | 0.7825 |
01:08 ET | 600 | 0.7821 |
01:10 ET | 600 | 0.7797 |
01:12 ET | 735 | 0.777 |
01:14 ET | 400 | 0.7797 |
01:15 ET | 520 | 0.7797 |
01:19 ET | 100 | 0.7797 |
01:21 ET | 400 | 0.7769 |
01:24 ET | 100 | 0.7825 |
01:32 ET | 100 | 0.7825 |
01:33 ET | 838 | 0.7769 |
01:37 ET | 200 | 0.7769 |
01:39 ET | 100 | 0.7769 |
01:42 ET | 100 | 0.7769 |
01:44 ET | 100 | 0.7769 |
01:53 ET | 228 | 0.7769 |
01:57 ET | 2126 | 0.775 |
02:00 ET | 1000 | 0.775 |
02:04 ET | 100 | 0.775 |
02:08 ET | 100 | 0.775 |
02:09 ET | 200 | 0.7716 |
02:11 ET | 450 | 0.78 |
02:18 ET | 100 | 0.7769 |
02:20 ET | 100 | 0.7715 |
02:26 ET | 100 | 0.7715 |
02:31 ET | 100 | 0.7716 |
02:40 ET | 4449 | 0.7696 |
02:42 ET | 300 | 0.7787 |
02:44 ET | 100 | 0.768 |
02:45 ET | 100 | 0.768 |
02:47 ET | 300 | 0.7675 |
02:49 ET | 200 | 0.7675 |
02:51 ET | 100 | 0.7675 |
02:54 ET | 100 | 0.7675 |
02:56 ET | 213 | 0.7661 |
03:03 ET | 410 | 0.7757 |
03:09 ET | 3200 | 0.767 |
03:12 ET | 100 | 0.767 |
03:14 ET | 300 | 0.767 |
03:16 ET | 100 | 0.767 |
03:18 ET | 200 | 0.767 |
03:25 ET | 200 | 0.7735 |
03:30 ET | 100 | 0.7696 |
03:32 ET | 200 | 0.7696 |
03:34 ET | 100 | 0.7774 |
03:36 ET | 500 | 0.7696 |
03:38 ET | 900 | 0.77 |
03:41 ET | 3828 | 0.7737 |
03:43 ET | 868 | 0.7737 |
03:45 ET | 563 | 0.7769 |
03:48 ET | 800 | 0.77 |
03:50 ET | 300 | 0.77 |
03:52 ET | 300 | 0.7773 |
03:54 ET | 350 | 0.7773 |
03:56 ET | 1000 | 0.773 |
03:57 ET | 7664 | 0.774 |
03:59 ET | 2196 | 0.7782 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Cara Therapeutics Inc | 42.5M | -0.4x | --- |
ImmuCell Corp | 39.4M | -6.7x | --- |
Prenetics Global Ltd | 63.8M | -1.1x | --- |
Aadi Bioscience Inc | 52.1M | -0.9x | --- |
Turnstone Biologics Corp | 62.9M | -1.0x | --- |
Viaderma Inc | 12.3M | 0.0x | --- |
Cara Therapeutics, Inc. is a development-stage biopharmaceutical company. The Company is focused on treatment paradigm to improve the lives of patients suffering from chronic pruritus. It is developing an oral formulation of difelikefalin, a selective, predominantly peripherally acting, non-scheduled Kappa opioid receptor agonist, for the treatment of chronic neuropathic pruritus associated with Notalgia Paresthetica (NP), a common, underdiagnosed neuropathy affecting the upper back. It is conducting Phase II/III Clinical Program in NP. The program is comprised of two studies - KOURAGE 1 and KOURAGE 2, which are double-blind, placebo-controlled, eight-week studies with patients allowed to roll-over into open-label 52-week extensions. It has developed an IV formulation of difelikefalin, for the treatment of moderate-to-severe pruritus associated with advanced chronic kidney disease in adults undergoing hemodialysis. The IV formulation is out-licensed worldwide.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $42.5M |
---|---|
Revenue (TTM) | $21.0M |
Shares Outstanding | 54.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.82 |
EPS | $-2.19 |
Book Value | $1.05 |
P/E Ratio | -0.4x |
Price/Sales (TTM) | 2.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -579.43% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.